Avantor Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6.6B-3.4% YoYTTM through 31 Mar 2026
Net Income -$551.4M-177.5% YoYTTM through 31 Mar 2026
Free Cash Flow $438.9MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 32.7% |
| EBITDA Margin | 1.9% |
| Operating Margin | 1.9% |
| Net Margin | -8.4% |
Returns
-9.5%ROE
-4.5%ROA
Balance Sheet Health
Debt / Equity0.71x
Current Ratio1.78x
Net Debt$3.6B
Cash & Equivalents$279.3M
Quality Metrics
Altman Z-Score1.79
Piotroski F-Score4 / 9
FCF Margin6.7%
Rule of 407.3
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $6.6B
Diluted EPS-$0.81TTMFY2025: $-0.78
Dividend
No dividend
Capital Allocation
Capex Intensity2.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Laboratory Solutions | $4.4B | -4.6% | View detailsEffective Q1 2026, Avantor is realigning its segments into VWR Distribution & Services and Bioscience & Medtech Products. |
| Bioscience Production | $2.2B | -1.0% | View detailsEffective Q1 2026, Avantor is realigning its segments into VWR Distribution & Services and Bioscience & Medtech Products. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.